Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Email

Leukemia Steering Committee

The NCI Leukemia Steering Committee (LKSC) was established in 2009. At monthly meetings, it addresses the design, prioritization, and evaluation of concepts for phase 2 and phase 3 clinical trials in adult leukemia. View the LKSC member roster as of April 08, 2025.

Clinical Trial Planning Meetings (CTPMs)

CTPMs are held periodically and focus on specific clinical trial-related topics. The following are important LKSC CTPMs:

  • Acute Myelogenous Leukemia (AML) Working Group
    A series of teleconferences during 2014 and 2015 focused on the development of biomarker-driven trials in AML in older patients. This effort culminated in two in-person meetings in December 2015 and June 2016 to achieve consensus on the details of trial design. 
  • Minimal Residual Disease in Adult Leukemia
    Minimal residual disease (MRD) is the level or extent of leukemic cells remaining in the blood after initial treatment measured by either flow cytometry or DNA-based methods. It is an important prognostic tool but requires standardization for use in clinical trials. Two workshops were held in 2012 to address standardization.

Contact

For more information, contact NCI CCCT Program Director, Elena Schwartz, Ph.D. at elena.schwartz@nih.gov.

Email